BCRX Q1 2021 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+295.2% YoY

Gross Profit

$13M68.9% margin

Operating Income

-$51M-269.6% margin

Net Income

-$64M-337.3% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+374.6%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$61M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$284M

Total Liabilities

$359M

Stockholders' Equity

-$75M

Cash & Equivalents

$227M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$5M	+295.2%
Gross Profit	$13M	$5M	+176.3%
Operating Income	-$51M	-$41M	-25.4%
Net Income	-$64M	-$38M	-71.0%

Revenue Segments

Collaborative and Other Research and Development

$2M100%